

The ESTABLISHED TEST
FOR EXTENDED ENDOCRINE
THERAPY DECISION-MAKING

Expanded Indication!

Navigate new order options and test reports to help set clear endocrine therapy recommendations from the start.

Table of Contents

Patient Eligibility.....1

Criteria for Patient Eligibility.

When to Order.....2

The established test for extended endocrine therapy, with new results to support earlier decision-making.

How to Order.....4

Navigating new order options for the Breast Cancer Index test.

Navigating Test Results.....7

Review new test reports for the Breast Cancer Index test.

Patient Eligibility

Patient criteria that must be met for testing.

Criteria	
Biologically female	✓
LN- or LN+ (1-3)	✓
Invasive Ductal and/or Lobular Histology	✓
HR+ (ER+ and/or PR+)	✓
Tumor Stage (pT1, pT2, pT3)	✓
Tumor Grade (1,2,3)	✓
HER2- or HER2+	✓
Pre-, Peri- or Post-menopausal	✓
Pre-treated specimen is required for testing	✓
No evidence of distant recurrence	✓

Contact Client Services for Support

☎ (877) 886-6739

✉ ClientServices@biotheranostics.com

Register for the Provider Portal

🌐 www.HologicProviderPortal.com



Scan QR Code
to register

When to Order the Breast Cancer Index® (BCI™) Test

The established test for extended endocrine therapy, with new results to support earlier decision-making.

Diagnosis

Primary adjuvant endocrine therapy

Year 5

Extended adjuvant endocrine therapy

Year 10

Time of Diagnosis:

As patients prepare to start endocrine therapy, set clear expectations about their treatment plan by ordering BCI testing to help inform:

- **Postmenopausal** - Endocrine therapy duration: 10 years? 5 years? Even Less?
- **Premenopausal** - Ovarian Function Suppression (OFS)? 5 vs. 10 years of endocrine therapy?

Years 1 - 3 1/2:

If patients are struggling with side effects on endocrine therapy, order BCI testing to help:

- Gain comfort in helping patients avoid unnecessary side effects when appropriate.
- Gain commitment to treatment adherence.

Approaching Year 5:

Predict whether patients are likely to benefit from extended endocrine therapy to inform whether to extend or end endocrine therapy at the 5-year mark.

Beyond Year 5:

For patients already continuing endocrine therapy beyond 5 years, predict if continuing to 10 is likely to be beneficial or if the additional exposure to side effects and toxicities may be avoided.

Consider the Full 0-10 Year Report

NEW!

Sample Full 0-10 Year Two Page Report

Sample Full 0-10 Year Two Page Report

Consider the 5-10 Year Report

The established test for extended endocrine therapy decision-making.

Sample 5-10 Year One Page Report

How to Order BCI Testing

Navigating new order options for the BCI test.

BCI Testing Options

The established test for extended endocrine therapy, with new options to support full primary and extended adjuvant endocrine therapy planning from the start.



Breast Cancer Index® Test Requested *Select one*

Postmenopausal

NEW!

☐ **Full 0-10 Year Report** - Risk of overall (0-10 year) distant recurrence to inform primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

☐ **5-10 Year Report** - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

Premenopausal

NEW!

☐ **Full 0-10 Year Report** - Risk of overall (0-10 year) distant recurrence to inform addition of OFS* to primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

☐ **5-10 Year Report** - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

*Predictive results for extended endocrine therapy benefit valid upon patient remaining distant recurrence-free following completion of primary adjuvant endocrine therapy. *Ovarian function suppression.



Step 1: Menopausal Status

Distinguishing the appropriate menopausal status helps ensure individualized recurrence risk estimates are provided on the Breast Cancer Index test report.

Breast Cancer Index® Test Requested *Select one*

Postmenopausal

☐ **Full 0-10 Year Report** - Risk of overall (0-10 year) distant recurrence to inform primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

☐ **5-10 Year Report** - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

Premenopausal

☐ **Full 0-10 Year Report** - Risk of overall (0-10 year) distant recurrence to inform addition of OFS* to primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

☐ **5-10 Year Report** - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

*Predictive results for extended endocrine therapy benefit valid upon patient remaining distant recurrence-free following completion of primary adjuvant endocrine therapy. *Ovarian function suppression.

Guidance:

- ▶ Select a test option based on patient’s menopausal status
- ▶ Postmenopausal is typically defined as 12 months without menses, or estradiol levels of less than 10pg/mL

Step 2: Full 0-10 Year vs. 5-10 Year Report

Breast Cancer Index® Test Requested *Select one*

Postmenopausal

NEW!

☐ **Full 0-10 Year Report** - Risk of overall (0-10 year) distant recurrence to inform primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

☐ **5-10 Year Report** - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

Premenopausal

NEW!

☐ **Full 0-10 Year Report** - Risk of overall (0-10 year) distant recurrence to inform addition of OFS* to primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

☐ **5-10 Year Report** - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

*Predictive results for extended endocrine therapy benefit valid upon patient remaining distant recurrence-free following completion of primary adjuvant endocrine therapy. *Ovarian function suppression.

NEW! Guidance for selecting the Full 0-10 Year Report:

- ▶ Includes new results to support primary adjuvant endocrine therapy decisions (page 1), in addition to the extended endocrine therapy results reported (page 2)
- ▶ May be used to help guide endocrine therapy planning from the start:
 - **Postmenopausal patients:** Help inform the duration of endocrine therapy (5 years vs. 10 years vs. even less if clinically indicated)
 - **Premenopausal patients:** Help inform the addition of Ovarian Function Suppression (OFS), as well as 5 vs. 10 years of endocrine therapy
- ▶ Appropriate for patients who are recently diagnosed or are within 3.5 years post-diagnosis

Guidance for selecting the 5-10 Year Report:

- ▶ Includes only results to inform extended endocrine therapy
- ▶ Appropriate for patients who are approaching or already beyond the 5-year mark post-diagnosis and are distant-recurrence free
- ▶ This option most closely mirrors the existing BCI test report

Navigating the BCI Test Results

NEW! Full 0-10 Year Report


PREMENOPAUSAL

Ovarian Function Suppression (OFS)? 5 vs. 10 years of endocrine therapy?


Page 1: Results to Inform Adjuvant Therapy

Prognostic Result: Overall distant recurrence in years 0-10 post-diagnosis.

BCI testing identifies node-negative (N0) patients at Minimal Risk of recurrence (<5%) even without the addition of OFS to primary adjuvant endocrine therapy.



For non-Minimal Risk patients, an individualized 10-year risk of recurrence is reported based on treatment with 5 years of adjuvant endocrine therapy including those treated with OFS.



Page 2: Results to Inform Extended Endocrine Therapy

Refer to 5-10 Year Report on page 9 - these results are included as page 2 in the Full 0-10 Year Report.


Navigating the BCI Test Results

5-10 Year Report (also included as Page 2 of Full 0-10 Year Report)

PRE- AND POST-MENOPAUSAL

5 vs. 10 years of endocrine therapy?

Results to Inform Extended Endocrine Therapy



Predictive Result

1 Reports whether the patient is likely to benefit from extended endocrine therapy. Reported as a clear **“YES”** or **“NO”**.

Prognostic Result

Reports the patient’s individual risk of late distant recurrence in years 5-10.

Depending whether the patient is likely to benefit from extended endocrine therapy (predictive result YES/NO) the report illustrates the recurrence risk if therapy is stopped at year 5 vs. continued to year 10.

- 2a If Predictive YES:** Report illustrates that risk of late distant recurrence may be reduced by 58-67% if patient continues endocrine therapy for 10 years vs stopping at year 5.
- 2b If Predictive NO:** Report illustrates that risk of late distant recurrence is likely to remain the same whether 5 vs. 10 years of endocrine therapy are completed.

New Order Options and Test Results Now Available

Order the established test for
extended endocrine therapy decisions,
now with additional results to unlock
earlier treatment planning.



Order the
Breast Cancer Index Test

Breast Cancer Index results are adjunctive to the ordering physician's workup; treatment decisions require correlation with all other clinical findings. For the Breast Cancer Index test intended use and limitations, visit BreastCancerIndex.com.

MRK-MISC002-001 Rev 2.0 © 2026 Hologic, Inc. All rights reserved. Hologic, Biotheranostics, Breast Cancer Index, BCI, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners.

Breast Cancer Index®